Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data;Coxibs, quel réel progrès thérapeutique?: Données pharmacoépidémiologiques récentes

Therapie

Volumn 59, Issue 2, 2004, Pages 201-205

  Montastruc, Jean Louis ^a,b   Lapeyre Mestre, Maryse ^a   Gony, Mireille ^a   Lugardon, Stephanie ^a   Bagheri, Haleh ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Adverse drug reactions; Celecoxib; Coxibs; Nonsteroidal anti inflammatory drugs; Pharmacoepidemiology; Pharmacovigilance; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; TENOXICAM;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART INFARCTION; HUMAN; MEDICAL PRACTICE; META ANALYSIS; NAUSEA; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 3543108354     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004039     Document Type: Conference Paper

References (25)

1. Montastruc JL. Pharmacologie: gare au mirage de la « sélectivité ». Rev Prescr 2003; 236: 152-3
2. International Society of Drug Bulletins. Ce que sont les véritables progrès thérapeutiques dans le domaine du Médicament. Rev Prescr 2002; 22: 140-5
3. Wilson RJ. Efficacy and safety of COX 2 inhibitors. BMJ 2002; 325: 607-8
4. Deeks JJ, Smith LA, Matthew DB. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 1-8
5. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284: 1947-55
6. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343: 1520-8
7. Juni P, Rugjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-8
8. Mamdani M, Rochon PA, Juurlink D, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 1-6
9. Layton D, Riley J, Wilton LV, et al. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2002; 55: 166-74
10. Anonymous. Non-steroidal anti-inflammatory drugs (NSA1Ds) and gastrointestinal (G1) safety. Curr Probl Pharmacovigilance 2002; 28: 5
11. Bannwarth B, Treves R, Euller-Ziegler L. et al. Adverse events associated with rofecoxib therapy: results of a large study in community derived osteoarthritic patients. Drug Saf 2003; 26: 49-54
12. Desboeuf K, Lapeyre-Mestre M, Montastruc JL. Risk of gastrointestinal haemorrhage with calcium antagonists. Br J Clin Pharmacol 1998; 46: 87-9
13. Bareille MP, Montastruc JL, Lapeyre-Mestre M. Atteintes hépatiques et médicaments anti-inflammatoires non stéroïdiens: étude cas/non-cas dans la Banque Nationale de Pharmacovigilance. Thérapie 2001; 56: 51-5
14. Garcia Rodriguez LA, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with kctorolac, other non steroidal anti-inflammatory drugs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 1998; 158: 33-9
15. Murkherjee D, Nissen E, Topol E. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286: 954-9
16. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction. Drug Saf 2002; 25: 829-35
17. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenasc-2 inhibitors. Arthritis Rheum 2002; 4: 349-55
18. Ray WA, Stein CM, Daugherty JR. et al. COX-2-selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3
19. Jackson LM, Hawkey CJ. COX-2-selective non-steroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000; 59: 1207-6
20. Noroian G, Clive D. Cyclo-oxygcnase-2 inhibitors and the kidney. Drug Saf 2002; 25: 165-72
21. Schneider F, Meziani F, Chartier C, et al. Fatal allergic vasculitis associated with celecoxib. Lancet 2002; 359: 852-3
22. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides?: revisiting the meaning of sulfa allergy. Drug Saf 2001; 24: 239-47
23. Bennett K, Teeling M, Feely J. Factors influencing switching from non-selective to selective non-steroidal anti-inflammatory drugs (NSAIDS) [abstract]. Br J Clin Phannacol 2003; 55: 448
24. Teeling M, Bennett K, Feely J. Have COX 2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs [abstract]? Br J Clin Pharmacol 2003; 55: 419
25. Boers M. NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222-3